A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

Afatinib is an oral, ErbB family blocker, which covalently binds and irreversibly blocks all kinase-competent ErbB family members. This phase II, open-label, single-arm study explored afatinib activity in human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients progressing aft...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lin, Nancy U., Winer, Eric P., Wheatley, Duncan, Carey, Lisa A., Houston, Stephen, Mendelson, David, Munster, Pamela, Frakes, Laurie, Kelly, Steve, Garcia, Agustin A., Cleator, Susan, Uttenreuther-Fischer, Martina, Jones, Hilary, Wind, Sven, Vinisko, Richard, Hickish, Tamas
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2012
Assuntos:
Clinical Trial
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3387495/
https://ncbi.nlm.nih.gov/pubmed/22418700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-012-2003-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados